Cancer

FormaPath demonstrate ‘mini’ nToto at CAP

FormaPath made a major unveiling with their exhibit at the 2024 College of American Pathologists Annual Meeting - a desktop…

1 year ago

HKUST Spearheads Four Large AI Models to Revolutionize Healthcare

HONG KONG, Oct. 31, 2024 /PRNewswire/ -- In a groundbreaking initiative, The Hong Kong University of Science and Technology (HKUST)…

1 year ago

Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting

New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow,…

1 year ago

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS, Oct. 31, 2024 /PRNewswire/ -- French…

1 year ago

FluoSphera Expands Its Systemic Technology Platform to empower ADCs to meet their promise

GENEVA and BOSTON Oct. 31, 2024 /PRNewswire/ -- FluoSphera, the leader in systemic drug discovery, is excited to announce its strategic…

1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative…

1 year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit…

1 year ago

Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer

Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,…

1 year ago

New Treatments, Novel Research Drive Better Survival Rates for Canadians with Lung Cancer, Offering Hope to Thousands: Lung Health Foundation

Lung Cancer Awareness Month: Survivors Share Stories of Hope and Resilience Amid Revolutionary Medical BreakthroughsTORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE)…

1 year ago